Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lynparza in Primary Ovarian and Breast Cancer (Pre-Surgical Window)
NCT04041128Phase 1Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Jul 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olaparib in ovarian cancer and breast cancer, sponsored by UT Southwestern Medical Center. Primary endpoints: DNA damage response to PARP inhibition at 7 days, Changes in ADP ribosylation to PARP inhibition at 7 days and 1 more. Started Jul 2019; status: completed.
02
Drugs
olaparib
03
Conditions
ovarian cancerbreast cancer
Beyond the preview
Go deeper on NCT04041128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04041128.